Coherus Oncology (CHRS) Stock: Buy, Sell, or Hold?
CHRS - Coherus Oncology, Inc. Common Stock
$1.43
0.10 (7.52%)
â˛
5d:
+0.7%
30d:
+25.44%
90d:
+2.14%
WAIT
LOW Confidence
Analysis Updated: Sep 14, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When CHRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CHRS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CHRS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CHRS is currently trading at $1.43, which is considered slightly high relative to its 30-day fair value range of $1.24 to $1.41.
Technical Outlook: Technically, CHRS is in a strong uptrend. The price is approaching resistance at $1.44. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.5% recently.
Market Sentiment: CHRS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.75 (+442.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CHRS is in a strong uptrend. The price is approaching resistance at $1.44. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.5% recently.
Market Sentiment: CHRS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.75 (+442.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.24 -
$1.41
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.4%
All Signals
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.5%)
- BULLISH: Trading 442.0% below Wall St target ($7.75)
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.24 -
$1.41
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.30
Resistance Level
$1.44
Current Trend
Strong Uptrend
Technical data as of
Sep 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.27
Wall Street Target
$7.75
(+442.0%)
Revenue Growth (YoY)
39.5%
Earnings Growth (YoY)
-75.5%
Profit Margin
-259.4%
Share & Embed Analysis
Last updated: September 15, 2026 6:08 AM ET
Data refreshes hourly during market hours. Next update: 7:08 AM
Data refreshes hourly during market hours. Next update: 7:08 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CHRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 52 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$27 | 48 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 49 HOLD |
